A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus

Journal of Clinical Investigation

Volumn 119, Issue 10, 2009, Pages 3115-3126

  Jian, Hua Li ^a   Chou, Chung Lin ^b   Li, Bo ^a   Gavrilova, Oksana ^a   Eisner, Christoph ^a   Schnermann, Jürgen ^a   Anderson, Stasia A ^b   Deng, Chu Xia ^a   Knepper, Mark A ^b   Wess, Jürgen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2 RECEPTOR STIMULATING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RADIOLIGAND; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN V2 RECEPTOR; AQP2 PROTEIN, MOUSE; AQP3 PROTEIN, MOUSE; AQUAPORIN 2; AQUAPORIN 3; ETHER DERIVATIVE; ONO AE1 329; ONO-AE1-329; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIURESIS; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENE DELETION; GENE EXPRESSION; LIGAND BINDING; MALE; MOUSE; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; X CHROMOSOME LINKED DISORDER; ANIMAL; CYTOLOGY; DRUG POTENTIATION; GENETICS; KIDNEY; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; AQUAPORIN 2; AQUAPORIN 3; DIABETES INSIPIDUS, NEPHROGENIC; DISEASE MODELS, ANIMAL; GENE DELETION; GENETIC DISEASES, X-LINKED; KIDNEY; KIDNEY CONCENTRATING ABILITY; KIDNEY TUBULES, COLLECTING; MALE; METHYL ETHERS; MICE; MICE, KNOCKOUT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, VASOPRESSIN;

EID: 70349655689     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39680     Document Type: Article

References (49)

1. Knoers, N., and Monnens, L.A. 1992. Nephrogenic diabetes insipidus: clinical symptoms, pathogenesis, genetics and treatment. Pediatr. Nephrol. 6:476-482.
2. Bichet, D.G., and Fujiwara, T.M. 1998. Diversity of nephrogenic diabetes insipidus mutations and importance of early recognition and treatment. Clin. Exp. Nephrol. 2:253-263.
3. Oksche, A., and Rosenthal, W. 1998. The molecular basis of nephrogenic diabetes insipidus. J. Mol. Med. 76:326-337. (Pubitemid 28168331)
4. Nielsen, S., Kwon, T.H., Frøkiaer, J., and Agre, P. 2007. Regulation and dysregulation of aquaporins in water balance disorders. J. Intern. Med. 261:53-64. (Pubitemid 46046472)
5. Bichet, D.G. 2008. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin. Nephrol. 28:245-251. (Pubitemid 351756520)
6. Holtzman, E.J., and Ausiello, D.A. 1994. Nephrogenic diabetes insipidus: causes revealed. Hosp. Pract. (Off. Ed.). 29:89-93, 97-98, 103-104.
7. Birnbaumer, M. 2001. The V2 vasopressin receptor mutations and fluid homeostasis. Cardiovasc. Res. 51:409-415. (Pubitemid 32718589)
8. Nielsen, S., et al. 1995. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 92:1013-1017.
9. DiGiovanni, S.R., Nielsen, S., Christensen, E.I., and Knepper, M.A. 1994. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc. Natl. Acad. Sci. U. S. A. 91:8984-8988.
10. Ecelbarger, C.A., et al. 1995. Aquaporin-3 water channel localization and regulation in rat kidney. Am. J. Physiol. 269:F663-F672. (Pubitemid 3006016)
11. Spanakis, E., Milord, E., and Gragnoli, C. 2008. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J. Cell Physiol. 217:605-617.
12. 2 vasopressin receptor gene. J. Clin. Invest. 106:1361-1371.
13. Suzawa, T., et al. 2000. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 141:1554-1559. (Pubitemid 32269125)
14. Lakso, M., et al. 1996. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. U. S. A. 93:5860-5865. (Pubitemid 26190768)
15. Hayashi, S., and McMahon, A.P. 2002. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244:305-318. (Pubitemid 34450645)
16. Yang, B., Zhao, D., Qian, L., and Verkman, A.S. 2006. Mouse model of inducible nephrogenic diabetes insipidus produced by floxed aquaporin-2 gene deletion. Am. J. Physiol. Renal Physiol. 291:F465-F472. (Pubitemid 44148136)
17. Ostrowski, N.L., Young, W.S. III, Knepper, M.A., and Lolait, S.T. 1993. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 133:1849-1859.
18. 1a receptor antagonists of vasopressin. Int. J. Pept. Protein Res. 40:261-267.
19. 2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 170:473-512.
20. Fenton, R.A., and Knepper, M.A. 2007. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol. Rev. 87:1083-1112.
21. Jacob, V.A., et al. 2008. Magnetic resonance imaging of urea transporter knockout mice shows renal pelvic abnormalities. Kidney Int. 74:1202-1208.
22. Breyer, M.D., and Breyer, R.M. 2001. G protein-coupled prostanoid receptors and the kidney. Annu. Rev. Physiol. 63:579-605.
23. Sugimoto, Y., and Narumiya, S. 2007. Prostaglandin E receptors. J. Biol. Chem. 282:11613-11617.
24. Burg, M.B. 1972. Perfusion of isolated renal tubules. Yale J. Biol. Med. 45:321-326.
25. Yang, B., Gillespie, A., Carlson, E.J., Epstein, C.J., and Verkman, A.S. 2001. Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus. J. Biol. Chem. 276:2775-2779. (Pubitemid 37376656)
26. Lloyd, D.J., Hall, F.W., Tarantino, L.M., and Gekakis, N. 2005. Diabetes insipidus in mice with a mutation in aquaporin-2. PLoS Genet. 1:e20.
27. Rojek, A., Füchtbauer, E.M., Kwon, T.H., Frøkiaer, J., and Nielsen, S. 2006. Severe urinary concentrating defect in renal collecting duct-selective AQP2 conditional-knockout mice. Proc. Natl. Acad. Sci. U. S. A. 103:6037-6042.
28. Sohara, E., et al. 2006. Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. Proc. Natl. Acad. Sci. U. S. A. 103:14217-14222. (Pubitemid 44453006)
29. Shi, P.P., et al. 2007. Nephrogenic diabetes insipidus in mice caused by deleting COOH-terminal tail of aquaporin-2. Am. J. Physiol. Renal Physiol. 292:F1334-F1344.
30. Brown, D., Katsura, T., and Gustafson, C.E. 1998. Cellular mechanisms of aquaporin trafficking. Am. J. Physiol. 275:F328-F331.
31. Loonen, A.J., Knoers, N.V., van Os, C.H., and Deen, P.M. 2008. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin. Nephrol. 28:252-265. (Pubitemid 351749753)
32. Verkman, A.S. 2008. Dissecting the roles of aquaporins in renal pathophysiology using transgenic mice. Semin. Nephrol. 28:217-226.
33. Uawithya, P., Pisitkun, T., Ruttenberg, B.E., and Knepper, M.A. 2008. Transcriptional profiling of native inner medullary collecting duct cells from rat kidney. Physiol. Genomics. 32:229-253. (Pubitemid 351186330)
34. Alexander, S.P., Mathie, A., and Peters, J.A. 2007. Guide to receptors and channels. Br. J. Pharmacol. 150(Suppl. 1):S1-S168.
35. 2 actions in the microcirculation of rat kidney. Am. J. Physiol. Renal Physiol. 279:F755-F764.
36. 4 receptors. Circ. Res. 86:663-670.
37. Klussmann, E., Maric, K., and Rosenthal, W. 2000. The mechanisms of aquaporin control in the renal collecting duct. Rev. Physiol. Biochem. Pharmacol. 141:33-95.
38. Hasler, U., et al. 2002. Long term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells. J. Biol. Chem. 277:10379-10386. (Pubitemid 34968157)
39. Bouley, R., Hasler, U., Lu, H.A., Nunes, P., and Brown, D. 2008. Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Semin. Nephrol. 28:266-278. (Pubitemid 351756522)
40. 2-induced hypertension in conscious dogs. Am. J. Physiol. 237:H449-H454.
41. Boone, M., and Deen, P.M. 2009. Congenital nephrogenic diabetes insipidus: what can we learn from mouse models? Exp. Physiol. 94:186-190.
42. Pászty, C., et al. 1995. Lethal α-thalassaemia created by gene targeting in mice and its genetic rescue. Nat. Genet. 11:33-39.
43. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 84:911-921. (Pubitemid 26106860)
44. Xu, X., et al. 2001. Direct removal in the mouse of a floxed neo gene from a three-loxP conditional knockout allele by two novel approaches. Genesis. 30:1-6. (Pubitemid 32521147)
45. Pisitkun, T., et al. 2008. Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD. Am. J. Physiol. Renal Physiol. 295:F1030-F1043.
46. Chou, C.L., Rapko, S.I., and Knepper, M.A. 1998. Phosphoinositide signaling in rat inner medullary collecting duct. Am. J. Physiol. 274:F564-F572. (Pubitemid 28158360)
47. Wall, S.M., Han, J.S., Chou, C.-L., and Knepper, M.A. 1992. Kinetics of urea and water permeability activation by vasopressin in rat terminal IMCD. Am. J. Physiol. 262:F989-F998.
48. Qi, Z., et al. 2004. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am. J. Physiol. Renal Physiol. 286:F590-F596. (Pubitemid 38233654)
49. Faulhaber-Walter, R., et al. 2008. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J. Am. Soc. Nephrol. 19:722-730.